Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5213-5218

  Wang, Michael ^a   Oki, Yasuhiro ^a   Pro, Barbara ^a   Romaguera, Jorge Enrique ^a   Rodriguez, Maria Alma ^a   Samaniego, Felipe ^a   McLaughlin, Peter ^a   Hagemeister, Frederick ^a   Neelapu, Sattva ^a   Copeland, Amanda ^a   Samuels, Barry I ^a   Loyer, Evelyne M ^a   Ji, Yuan ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; METHOTREXATE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGRESSION; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA CELL; MALE; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 70449727887     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8545     Document Type: Article

References (26)

1. Rosenbluth BD, Yahalom J: Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 65:1185-1191, 2006
2. Leitch HA, Gascoyne RD, Chhanabhai M, et al: Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555-1561, 2003
3. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 7:750-762, 2007
4. Hiddemann W, Dreyling M: Mantle cell lymphoma: Therapeutic strategies are different from CLL. Curr Treat Options Oncol 4:219-226, 2003
5. Witzig TE: Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23:6409-6414, 2005
6. O'Connor OA: Mantle cell lymphoma: Identifying novel molecular targets in growth and survival pathways. Hematology Am Soc Hematol Educ Program 2007:270-276, 2007
7. Witzig TE: Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol 30:11-16, 2003
8. Morschhauser F, Illidge T, Huglo D, et al: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110:54-58, 2007
9. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005
10. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
11. Borghaei H, Schilder RJ: Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 34:4-9, 2004
12. Gordon LI: Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 30:23-28, 2003
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 17:1244, 1999
14. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
16. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006
17. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood 111:558-565, 2008
18. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
19. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
20. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
21. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356, 2005
22. Weigert O, von Schilling C, Rummel MJ, et al: Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin(R)) in patients with relapsed or refractory mantle cell lymphoma (MCL) after/not appropriate for autologous stem cell transplantation (ASCT) - A phase II trial of the European MCL Network. ASH Annual Meeting Abstracts 106:4786, 2005
23. Zelenetz AD, Noy A, Pandit-Taskar N, et al: Sequential radioimmunotherapy with tositumomab/ iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 24:436s, 2006 (suppl; abstr 7560)
24. Smith MR, Zhang L, Gordon LI, et al: Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Blood (ASH Annual Meeting Abstracts) 110:389, 2007
25. Czuczman MS, Emmanouilides C, Darif M, et al: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25:4285-4292, 2007
26. Ansell SM, Ristow KM, Habermann TM, et al: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20:3885-3890, 2002